ClinicalTrials.gg
RecruitingNCT05674175Updated Mar 27, 2026

Co-administration of CART22-65s and huCART19 for B-ALL

A Phase 1/2 interventional study of Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) and Autologous, humanized anti-CD19 CAR T cell therapy (huCART19) in B-cell Acute Lymphoblastic Leukemia and B Lineage Lymphoblastic Lymphoma, sponsored by Stephan Grupp MD PhD. Recruiting at 1 site in United States. Open to participants aged Up to 29 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Stephan Grupp MD PhD · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
93
Allocation
Non-randomized
Ages
Up to 29 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 725 studies in Burkitt Lymphoma with a site in United States — 70 open to participants now, 118 under way, 10 of them phase 3. Burkitt Lymphoma · United States.

Planned enrollment
108th of 594
93 · median 37
Started
2023
with 16 others
Phase 1/2
83 of 725
14 open now
Primary completion
2028-07
later than 79 of 117 live
Registered
676th of 725
by date

Among the 725 studies in Burkitt Lymphoma with a site in United States, this one is the 108th largest by planned enrollment of the 594 interventional ones that give a count, is one of 17 that started in 2023, is one of 83 in phase 1/2, reaches primary completion later than 79 of the 117 other live ones, and was the 676th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

70 of the 725 studies in Burkitt Lymphoma with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: Up to 29 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 725 studies in Burkitt Lymphoma with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

Read the detailed description

CD19-targeted CAR T cell therapy has transformed the treatment landscape for children and young adults with chemo-refractory or relapsed B cell Acute Lymphoblastic Leukemia (B-ALL). Despite remarkable initial response rates, approximately 50% of pediatric patients experience a subsequent disease relapse. The prognosis for these patients is dismal with a median survival of less than one year from the time of post-CART19 relapse. The primary mechanisms contributing to CART19 failure include CD19-antigen escape and loss of CAR T cell surveillance due to short CART persistence. This study aims to counter each driver of relapse by co-administering two next-generation CAR T cell products: an anti-CD22 CART (CART22-65s), designed to overcome CD19-antigen escape; and a humanized anti-CD19 CART (huCART19), designed to overcome immune-mediated rejection of murine CART19.

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma

Browse trials for

04

Who can participate

Ages eligible
Up to 29 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form
  2. Patients with documented CD19+ and/or CD22+ ALL/LLy:

    1. Cohort A: Patients with ALL/LLy:
    2. Cohort B: Patients with poor response to prior B cell directed engineered cell therapy
  3. Patients with prior or current history of Central Nervous System 3 disease will be eligible if Central Nervous System disease is responsive to therapy
  4. Documentation of CD19 and/or CD22 tumor expression in bone marrow, peripheral blood, Cerebrospinal fluid, or tumor tissue by flow cytometry at the time of last detectable disease. If the patient has experienced a relapse after CD19-directed and/or CD22-directed therapy, flow cytometry should be evaluated after this therapy to demonstrate CD19 and/or CD22 expression.
  5. Age 0-29 years
  6. Adequate organ function
  7. Adequate performance status defined as Lanksy or performance score ≥50.
  8. Subjects of must agree to use acceptable methods.

Exclusion criteria

Exclusion Criteria:

  1. Active or active
  2. infection
  3. Active acute or chronic Graft Vs. Host Disease requiring systemic therapy
  4. Concurrent use of systemic or at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy or immunosuppression during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well.
  5. Central nervous system disease that is progressive on therapy, or with Central nervous system parenchymal lesions that might increase the risk of central nervous system toxicity.
  6. Pregnant or nursing (lactating) women
  7. Uncontrolled active infection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    Dose Finding Arm

    Phase 1 will evaluate the safety of co-administration of CART22-65s with huCART19 in patients who experienced a disease relapse after prior CAR T cell therapy. There is no planned dose escalation but a dose-deescalation will be made based on the incidence of Dose Limiting Toxicities

    Biological: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) · Biological: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

  • Experimental
    Expansion Arm

    If at least one dose level of phase 1 is determined to be safe, the phase 2 dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of CART 22-65s and huCART19 cells that were determined to be safe. 2 cohorts are planned: Cohort A (relapsed/refractory, CAR T cell naïve) \& Cohort B (prior treatment with a prior CAR T cell product).

    Biological: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) · Biological: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

Interventions

  • BiologicalAutologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)

    CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain

    Also known as: CART22-65s

  • BiologicalHUCART19Studies of HUCART19HUCART19 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain

    Also known as: huCART19

06

What researchers measure

Primary outcomes

  1. Safety of CART22-65s and huCART19 co-administration

    The safety of the administering CART22-65s and huCART19 will be measured by the monitoring the frequency and severity of adverse events in patients with advanced or refractory B-Cell Acute Lymphoblastic Leukemia or B Cell Lymphoblastic Lymphoma (B-LLy), including those previously treated with cell therapy.

    Time frame: 1 year

  2. Efficacy of CART22-65s and huCART19 co-administration

    The efficacy of CART22-65s and huCART19 co-administration will be measured by the evaluating the overall response rate in patients with advanced or refractory B cell hematologic malignancies, including those previously treated with cell therapy.

    Time frame: 1 year

Secondary outcomes

  1. Manufacturing Feasibility

    The manufacturing feasibility of manufacturing both CART22-65s and huCART19 will be measured by the percentage of manufactured products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, sterility or due to tumor contamination.

    Time frame: 5 years

  2. Anti-tumor response due to CART22-65s and huCART19 co-administration

    Anti-tumor response due to CART22-65s and huCART19 co-administration will be measured by negative minimal residual disease (MRD) as measured by multiparameter flow cytometry at day 28.

    Time frame: Day 28

  3. Event Free Survival

    1-year Event-Free Survival (EFS) in subjects with relapsed/refractory B-ALL (Cohort A) and in subjects with poor response to prior B cell directed engineered cell therapy (Cohort B)

    Time frame: 1 year

  4. Relapse Free Survival

    1-year relapse-free survival (RFS) rate in CAR-naïve subjects with relapsed/refractory B-ALL (Cohort A) and in CAR-exposed subjects with poor response to prior B cell directed engineered cell therapy (Cohort B)

    Time frame: 1 year

  5. Overall Survival

    1-year overall survival (OS) rate in CAR-naïve subjects with relapsed/refractory B-ALL (Cohort A) and in CAR-exposed subjects with poor response to prior B cell directed engineered cell therapy (Cohort B).

    Time frame: 1 year

  6. CAR T Cell Therapy Persistence

    CART22-65s and huCART19 persistence polymerase chain reaction (or flow cytometry) analysis of whole blood to detect and quantify survival of CART2265s and huCART19 over time.

    Time frame: 1 year

  7. Bioreactivity of CART22-65s and huCART19 when co-administered

    The bioreactivity of CART22-65s and huCART19 when co-administered, as measured by elevations level in any of; Uric Acid, Lactate Dehydrogenase (LDH), c-reactive protein (CRP), and cytokines (e.g.IL -10) before and after CART T cell infusions.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jul 2028, 65 months after the start.

Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's planned 65 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Jan 6, 2023
StartActual
Jan 25, 2023
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2029
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05674175
Lead sponsor
Stephan Grupp MD PhD
Responsible party
Stephan Grupp MD PhD (Chief, Cell Therapy and Transplant Section Director, Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy Medical Director, Cell and Gene Therapy Lab, Children's Hospital of Philadelphia) — Sponsor-investigator
First posted
Jan 6, 2023
Start date
Jan 25, 2023
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Mar 27, 2026

Study contacts

CART Nurse Navigator
Contact
CARTNurseNavigator@chop.edu
445-942-5891
Melissa S. Varghese, M.S.
Contact
varghesem@chop.edu
8455535358
Regina Myers, MD
principal investigator · Children's Hospital of Philadelphia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HUCART19

Start the discussion